Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

MRNA - Moderna Inc Stock Price, Fair Value and News

$25.17+1.11 (+4.61%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MRNA Price Action

Last 7 days

0.6%

Last 30 days

1.0%

Last 90 days

3.7%

Trailing 12 Months

-40.9%

MRNA Stock Price

MRNA RSI Chart

MarAprMayJunJulAugSepOctNovDec0102030405060708090

MRNA Valuation

Market Cap

9.8B

Price/Earnings (Trailing)

-3.16

Price/Sales (Trailing)

2.93

EV/EBITDA

-2.98

Price/Free Cashflow

-3.71

MRNA Price/Sales (Trailing)

202320242025246810

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

3.2B

Rev. Growth (Yr)

-45.44%

Rev. Growth (Qtr)

615.49%

201820202022202405B10B15B20B

MRNA Earnings

Earnings (TTM)

-3.1B

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

75.76%

2018202020222024-5B05B10B15B

MRNA Profitability

EBT Margin

-97.44%

Return on Equity

-33.4%

Return on Assets

-25.68%

Free Cashflow Yield

-26.98%

MRNA Investor Care

Shares Dilution (1Y)

1.52%

Diluted EPS (TTM)

-8.07

MRNA Alerts

The Good News

Last Updated: 2025-12-04
Moderna, Inc. has secured a $1.5 billion credit facility to enhance its financial position and support its late-stage clinical pipeline, indicating a proactive financial strategy. The company is also targeting a 10% revenue growth by 2026 and aims to achieve cash breakeven by 2028, showcasing its commitment to improving operational efficiency. Source: The Globe and Mail, https://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/36315243/moderna-secures-15-billion-credit-facility/; Source: Benzinga, https://www.benzinga.com/trading-ideas/movers/25/11/48983817/whats-going-on-with-moderna-stock

The Bad News

Last Updated: 2025-12-04
Despite recent initiatives, Moderna faces significant challenges, including declining revenues and a negative P/E ratio, which have contributed to a Hold rating from analysts. The stock has dropped 3.47%, reflecting investor skepticism regarding the effectiveness of its growth strategies amidst broader market trends. Source: The Globe and Mail, https://www.theglobeandmail.com/investing/markets/stocks/MRNA-Q/pressreleases/36250839/moderna-announces-pipeline-progress-and-strategy-update/; Source: Benzinga, https://www.benzinga.com/trading-ideas/movers/25/11/48983817/whats-going-on-with-moderna-stock
Disclaimer: This information is generated using our AI model (beta) and may contain inaccuracies. Please verify the information from multiple sources.

Revenue Breakdown

As of: Jun 30, 2025
202220232024202501B2B3B4B5B6B7B
Product Sales
ProductValuePercent
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2017201820192020202120222023202405B10B15B20B
Net sales
YearQ1Q2Q3Q4
20250000
20245.9B5.0B4.1B3.2B
202315.1B10.7B9.1B6.8B
202222.6B23.0B21.4B19.3B
20212.7B7.0B11.8B18.5B
202052.2M106.1M246.1M803.0M
2019122.1M106.3M81.6M60.2M
2018204.5M192.3M191.6M135.1M
2017132.8M157.1M181.5M205.8M
2016000108.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEmodernatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3900

Moderna Inc Frequently Asked Questions

What is the ticker symbol for Moderna Inc? What does MRNA stand for in stocks?

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moderna Inc (MRNA)?

As of Wed Dec 03 2025, market cap of Moderna Inc is 9.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers.

Is Moderna Inc a good stock to buy?

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

What is Moderna Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MRNA's PE ratio (Price to Earnings) is -3.16 and Price to Sales (PS) ratio is 2.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.